Taris gets $12.5 million for bladder drug delivery candidate; Pfizer joins BIND for nanoparticle delivery;

> Taris Biomedical snagged $12.5 million in funding for its LiRIS candidate that delivers drugs directly to the bladder. 

> Pfizer ($PFE) inked a deal with BIND Biosciences, a Robert Langer venture, to get a piece of the nanoparticle drug delivery market. More

> Eli Lilly ($LLY) is pumping money into its facility devoted to filling insulin cartridges, investing $180 million in the plant, adding to the $140 million added last year. Story

> Researchers at the Johns Hopkins University School of Medicine have found that sublingual delivery of allergens could be effective for patients with allergic rhinitis. Article

> The FDA approved Tris Pharma's extended-release option for Karbinal, a drug to treat allergic rhinitis, in oral delivery form. Release

> Oramed ($ORMP) snagged Japanese approval of its patent on the oral delivery of proteins. Release

> A compound, cyclodextrin, used as an ingredient in other drugs is undergoing tests to determine whether it will improve other treatments by helping with the delivery of cholesterol to the brain. More